Developing Innovative, Effective Drug Therapies for Cancer Immunotherapy
Admune Therapeutics LLC is a clinical-stage biotech company focused on the development and delivery of cytokine therapy drugs for the treatment of various cancers. Our goal is to provide effective pharmaceutical products that improve the quality of life for oncology patients with metastatic cancers including melanoma, renal cell carcinoma, non-small cell lung cancers (NSCLC) and others.
Admune Therapeutics has received FDA authorization to move forward with a Phase I clinical study of our initial cytokine, hetIL-15. Enrollment for in-human studies has begun through the National Cancer Institute at the National Institutes of Health.